Akt

Akt inhibitors target Akt, also called protein kinase B (PKB), a serine/threonine kinase in cell survival signaling. In 1995 the Akt proto-oncogene product was identified as a target of phosphatidylinositol 3-kinase (PI3K) activated by platelet-derived growth factor. Insulin and insulin-like growth factor 1 activate the kinase through phosphorylation at Thr308 and Ser473. The three isoforms, Akt1, Akt2 and Akt3, phosphorylate substrates that control metabolism, proliferation and apoptosis. The category includes the allosteric inhibitor MK-2206 2HCl, the catalytic-site inhibitor capivasertib and the alkylphospholipid perifosine. SC79, by contrast, promotes Akt phosphorylation and serves as an activator in pathway studies.

Items 76-100 of 158

  • 5,4'-Dihydroxy-6,8-dimethoxy-7-O-rhamnosyl flavone
    Cat. No.
    A25654

    5,4'-Dihydroxy-6,8-dimethoxy-7-O-rhamnosyl flavone

    Synonyms: DDR

    5,4'-Dihydroxy-6,8-dimethoxy-7-O-rhamnosyl flavone is a potent Akt inhibitor derived from Indigofera ovata. This compound effectively disrupts the PI3K/AKT and NF-κB signaling pathways, leading to the inhibition of cancer cell invasion and migration. Its biological activity supports research applications in cancer therapeutics and molecular signaling studies.

    Out of stock

    All 3 sizes
  • Akt3 ligand-1
    Cat. No.
    A25655

    Akt3 ligand-1

    Akt3 ligand-1 is a potent inhibitor of Akt3, exhibiting an IC50 of 0.1 nM. This compound serves as a ligand for the development of PROTAC strategies targeting Akt3, facilitating targeted protein degradation. Akt3 ligand-1 is invaluable for research into cancer biology and cellular signaling pathways where Akt3 plays a pivotal role. Additionally, it can be utilized to synthesize PROTAC Akt3 Degrader-1, enabling further exploration of therapeutic potentials in oncological studies.

    Out of stock

    All 3 sizes
  • Akt1-IN-7
    Cat. No.
    A25658

    Akt1-IN-7

    Akt1-IN-7 is a potent Akt1 inhibitor with an IC50 value of less than 15 nM. It effectively hinders the activity of Akt1, a key player in cell survival and growth signaling pathways. This compound is utilized in research focused on cancer biology, metabolic disorders, and other conditions where Akt1 signaling is implicated. Its selective inhibition of Akt1 makes it a valuable tool for elucidating the role of this kinase in various biological processes.

    25 mg
    $1,495.00
    50 mg
    $1,975.00
    All 3 sizes
  • Monosialoganglioside GM3 (bovine)
    Cat. No.
    A25660

    Monosialoganglioside GM3 (bovine)

    Monosialoganglioside GM3 (bovine) is a ganglioside that functions as an Akt inhibitor, impacting both VEGFR2 and Akt signaling pathways. At a concentration of 20 μM, it effectively inhibits angiogenesis and decreases the proliferation and migration of human umbilical vein endothelial cells (HUVECs). Additionally, it protects against ferroptosis, which is relevant in the context of abdominal aortic aneurysm formation, and impairs insulin signaling by disrupting the insulin receptor-Caveolin-1 complex, contributing to insulin resistance in adipocytes. This reagent is applicable in cancer and metabolic disease research.

    1 mg
    $550.00
    5 mg
    $1,695.00
    All 2 sizes
  • Akt1-IN-4
    Cat. No.
    A25666

    Akt1-IN-4

    Akt1-IN-4 is a selective inhibitor of the AKT1-E17K mutant with an IC50 value of less than 15 nM. This compound effectively disrupts the activity of the AKT signaling pathway, which is implicated in various cancers. Akt1-IN-4 is suitable for research applications focused on studying the role of AKT1 mutations in tumorigenesis and therapeutic resistance.

    25 mg
    $1,405.00
    50 mg
    $1,790.00
    All 3 sizes
  • Puquitinib
    Cat. No.
    A25667

    Puquitinib

    Synonyms: XC-302 free base

    Puquitinib is a selective Akt inhibitor that effectively disrupts the PI3K/AKT/mTOR signaling pathway, promoting autophagy in nasopharyngeal carcinoma cells. This compound demonstrates a dose-dependent antiproliferative effect on CNE-2 cells, which is accompanied by increased autophagosome and autolysosome formation as confirmed by fluorescence and electron microscopy. Puquitinib enhances the conversion of LC3-I to LC3-II and elevates beclin 1 levels while decreasing p62 expression. Additionally, it induces apoptosis in CNE-2 cells, highlighting the interplay between autophagy and apoptosis in mediating cell death processes relevant to cancer research.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • TAT-TCL1-Akt-in
    Cat. No.
    A25669

    TAT-TCL1-Akt-in

    TAT-TCL1-Akt-in is an Akt inhibitor that selectively modulates the Akt signaling pathway, which is crucial for cell proliferation and survival. By inhibiting Akt activity, this compound can effectively impact various cellular processes linked to tumorigenesis and cancer progression. TAT-TCL1-Akt-in is useful for research applications focused on cancer biology, signaling pathways, and therapeutic interventions targeting the Akt pathway.

    Out of stock

    All 3 sizes
  • BI-69A11
    Cat. No.
    A25672

    BI-69A11

    BI-69A11 is a selective AKT inhibitor that effectively suppresses the phosphorylation of AKT, disrupting the signaling pathways associated with cell survival and proliferation. This compound demonstrates significant anticancer activity, promoting apoptosis in melanoma and prostate tumor cells. It serves as a valuable tool for research in cancer biology and therapeutic development targeting the AKT pathway.

    1 mg
    $20.00
    2 mg
    $25.00
    All 6 sizes
  • Royleanone
    Cat. No.
    A25676

    Royleanone

    Synonyms: NSC 122417

    Royleanone, a diterpenoid isolated from plants, inhibits the proliferation of cancer cells by inducing cell cycle arrest and mitochondria-mediated apoptosis, also inhibits cell migration potential, inhibits mTOR/PI3/AKT signaling pathway in LNCaP prostate cancer cells.

    5 mg
    $425.00
    All 1 sizes
  • AKT-IN-7
    Cat. No.
    A25679

    AKT-IN-7

    AKT-IN-7 (compound 1-P1) is a potent AKT inhibitor. AKT-IN-7 has the potential for cancer research.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • RLX hydrochloride
    Cat. No.
    A25685

    RLX hydrochloride

    Synonyms: PD 139530 hydrochloride

    RLX hydrochloride is a potent inhibitor of the PI3K/Akt/FoxO3a signaling pathway, which plays a critical role in cellular growth and survival. This compound demonstrates significant therapeutic potential in experimental colon cancer by modulating the tumor microenvironment and enhancing the efficacy of cancer immunotherapy. Additionally, RLX hydrochloride can improve the retention of therapeutic agents within tumors when utilized with advanced nanoparticle delivery systems. It may also be effectively combined with other treatment modalities, such as chemotherapy and radiotherapy, to optimize overall cancer therapy outcomes.

    1 mg
    $155.00
    5 mg
    $395.00
    All 7 sizes
  • AKT-IN-9
    Cat. No.
    A25686

    AKT-IN-9

    AKT-IN-9 is a potent inhibitor of AKT (Protein Kinase B), a key regulator of the PI3K/AKT/mTOR signaling pathway. This compound plays a critical role in processes such as cell growth, survival, differentiation, and metabolism. AKT-IN-9 is valuable for research applications focusing on breast and prostate cancer, contributing to a better understanding of tumor biology and potential therapeutic strategies.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • Tubulin/AKT1-IN-1
    Cat. No.
    A25687

    Tubulin/AKT1-IN-1

    Tubulin/AKT1-IN-1 is an inhibitor of tubulin polymerization and AKT pathway activation. This compound demonstrates significant inhibition of proliferation and metastasis in H1975 cells, along with a modest induction of apoptosis. Tubulin/AKT1-IN-1 is particularly relevant for research in non-small cell lung cancer (NSCLC), providing a valuable tool for studying therapeutic strategies against this malignancy.

    Out of stock

    All 3 sizes
  • AKT-IN-12
    Cat. No.
    A25690

    AKT-IN-12

    AKT-IN-12 is a selective Akt kinase inhibitor, exhibiting an IC50 value of 0.55 μM. It effectively induces G0/G1 cell cycle arrest and promotes apoptosis in target cells. Additionally, AKT-IN-12 inhibits phosphorylated AKT and ERK while activating JNK and phosphorylated JNK, making it a valuable reagent for research applications in leukemia studies.

    Out of stock

    All 3 sizes
  • AKT-IN-20
    Cat. No.
    A25692

    AKT-IN-20

    AKT-IN-20 is a selective inhibitor of the AKT kinase, a key regulator in numerous signaling pathways involved in cell growth, survival, and metabolism. This compound effectively impedes AKT activity, making it valuable for the study of cancer mechanisms and the exploration of potential therapeutic strategies. Its application is essential for researchers investigating the role of AKT in tumorigenesis and treatment resistance.

    1 mg
    $110.00
    2 mg
    $155.00
    All 8 sizes
  • Ipatasertib tosylate
    Cat. No.
    A25706

    Ipatasertib tosylate

    Synonyms: GDC-0068 tosylate; RG7440 tosylate

    Ipatasertib tosylate is a potent and selective ATP-competitive inhibitor of pan-Akt, exhibiting IC50 values of 5, 18, and 8 nM for Akt1, Akt2, and Akt3, respectively. By inhibiting Akt, Ipatasertib tosylate activates FoxO3a and NF-κB, resulting in p53-independent activation of PUMA and subsequent apoptosis in cancer cells. This compound demonstrates significant anti-tumor activity in xenograft mouse models, making it a valuable tool for cancer research and therapeutic development.

    Out of stock

    All 3 sizes
  • AKT-IN-22
    Cat. No.
    A25708

    AKT-IN-22

    AKT-IN-22 is a potent allosteric inhibitor of AKT, a key kinase involved in various cellular processes such as proliferation, survival, and glucose metabolism. Its inhibition of AKT has demonstrated significant anticancer effects, making it a valuable tool for cancer research. This compound is particularly useful for studying the mechanisms of AKT signaling pathways and exploring therapeutic strategies in oncology.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Doxazosin hydrochloride
    Cat. No.
    A25709

    Doxazosin hydrochloride

    Synonyms: UK 33274 hydrochloride

    Doxazosin hydrochloride is an Akt inhibitor that primarily targets postsynaptic α1-adrenoceptors in vascular smooth muscle. This compound exhibits vasodilatory effects, resulting in decreased peripheral vascular resistance, and is utilized in studies of hypertension and prostate hyperplasia. Additionally, Doxazosin hydrochloride has demonstrated the ability to inhibit the proliferation and migration of hepatic stellate cells in mouse liver fibrosis models, influencing fibrosis, autophagy, and apoptosis mechanisms through the activation of the PI3K/Akt/mTOR signaling pathway. It also disrupts autophagic flux, leading to enhanced apoptosis in hepatic stellate cells.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • AKT-IN-25
    Cat. No.
    A25711

    AKT-IN-25

    AKT-IN-25 is a selective inhibitor of Akt that targets its phosphorylation, thereby disrupting the PI3K/Akt/mTOR signaling pathway. This compound effectively arrests the cell cycle at the G1 phase and inhibits the migration and proliferation of pancreatic cancer cells, including PANC-1, PATU-T, and SUIT-2, with IC50 values of 3.05 μM, 1.32 μM, and 3.85 μM, respectively. AKT-IN-25 is a valuable tool for studying Akt-mediated cellular processes and therapeutic strategies in cancer research.

    Out of stock

    All 3 sizes
  • Acetyl-Exenatide
    Cat. No.
    A25712

    Acetyl-Exenatide

    Acetyl-Exenatide is an acetylated derivative of Exenatide, targeting the PI3K/Akt signaling pathway. This compound exhibits insulin-mimetic properties and is instrumental in type 2 diabetes research. Acetyl-Exenatide promotes Th17 differentiation while inhibiting Treg differentiation, and downregulates the phosphorylation of PI3K/Akt/FoxO1, making it a valuable tool for elucidating mechanisms underlying metabolic disorders.

    Out of stock

    All 3 sizes
  • SH-5
    Cat. No.
    A25715

    SH-5

    SH-5 is a potent inhibitor of the AKT signaling pathway. It enhances apoptosis triggered by tumor necrosis factor (TNF) and effectively blocks NF-kB activation induced by TNF-α, lipopolysaccharide, phorbol ester, and cigarette smoke. This compound is valuable for research applications involving cell survival, inflammation, and cancer biology.

    25 mg
    $1,275.00
    All 1 sizes
  • NISC-6
    Cat. No.
    A25723

    NISC-6

    NISC-6 is a dual inhibitor of Topoisomerase IIα and Akt, demonstrating significant inhibitory activity in various cancer cell lines, including UACC903 (IC50 = 2.5 µM) and CHL-1 (IC50 = 0.8 µM). This compound effectively induces both early and late apoptosis in a dose-dependent manner. NISC-6 is suitable for research focusing on melanoma and related therapeutic mechanisms.

    Out of stock

    All 3 sizes
  • Calebin A
    Cat. No.
    A25726

    Calebin A

    Calebin A is a potent inhibitor of the PI3K/Akt/mTOR pathway, as well as MAPK and NF-κB signaling pathways. It exhibits significant anti-tumor activity through epigenetic regulation and can suppress apoptosis while inhibiting autophagy. Additionally, Calebin A modulates adipogenesis, enhances thermogenic processes, and supports gut microbiota. This compound is suitable for research in various domains, including osteoarthritis, Alzheimer's disease, type 2 diabetes, malignant peripheral nerve sheath tumors, and colorectal cancer.

    1 mg
    $155.00
    5 mg
    $395.00
    All 6 sizes
  • AKT1-IN-11
    Cat. No.
    A25731

    AKT1-IN-11

    AKT1-IN-11 is a dual inhibitor targeting both AKT1 and tubulin, derived from Podophyllotoxin. This compound effectively down-regulates the phosphorylation of AKT kinase in tumor cells, leading to inhibited cell proliferation, a G2/M phase arrest, and the induction of apoptosis. Additionally, AKT1-IN-11 promotes tubulin depolymerization, making it a valuable tool for research into colorectal cancer and potential therapeutic strategies.

    Out of stock

    All 3 sizes
  • Akt1-IN-5
    Cat. No.
    A25735

    Akt1-IN-5

    Akt1-IN-5 is a potent Akt1 inhibitor with an IC50 of less than 15 nM. This compound selectively targets the Akt1 signaling pathway, which is crucial in regulating cell survival, metabolism, and proliferation. It is primarily used in cancer research to explore the therapeutic potential of modulating Akt1 activity in various tumor types.

    25 mg
    $1,405.00
    50 mg
    $1,790.00
    All 3 sizes

Items 76-100 of 158

Added to your cart

View Cart Checkout

    Loading...